abrdn plc Has $2.69 Million Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX)

abrdn plc increased its position in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 137.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 883,704 shares of the company’s stock after buying an additional 512,049 shares during the period. abrdn plc owned 1.66% of TScan Therapeutics worth $2,686,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TCRX. China Universal Asset Management Co. Ltd. acquired a new position in shares of TScan Therapeutics during the 4th quarter valued at about $32,000. Dimensional Fund Advisors LP bought a new stake in TScan Therapeutics during the second quarter worth approximately $70,000. The Manufacturers Life Insurance Company acquired a new position in TScan Therapeutics during the second quarter valued at approximately $90,000. SG Americas Securities LLC bought a new position in shares of TScan Therapeutics in the third quarter valued at approximately $78,000. Finally, Heck Capital Advisors LLC acquired a new stake in shares of TScan Therapeutics in the fourth quarter worth $61,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Stock Down 8.0 %

Shares of NASDAQ:TCRX opened at $2.18 on Monday. The company has a 50 day moving average of $2.97 and a 200-day moving average of $4.59. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. TScan Therapeutics, Inc. has a one year low of $2.18 and a one year high of $9.69. The stock has a market cap of $116.35 million, a price-to-earnings ratio of -2.06 and a beta of 0.87.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. On average, sell-side analysts forecast that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research note on Wednesday, December 11th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a research report on Monday, December 23rd.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.